Individuals with obstructive sleep apnea who breathed through their mouths >25% of the time failed to achieve stable breathing during oronasal CPAP therapy.
The benefit of CPAP was seen for depression but not anxiety symptoms in patients with obstructive sleep apnea.
Use of continuous positive airway pressure improved obstructive sleep apnea without any changes in the neurocognitive sphere or blood pressure readings in elderly patients.
Obstructive sleep apnea and the indices of severity are heritable, while daytime sleepiness is mostly influenced by environmental factors.
The Drug Enforcement Agency (DEA) has designated Sunosi (solriamfetol; Jazz Pharmaceuticals) a Schedule IV controlled substance.